1875P RATIONALE-304: Baseline genetic alterations in tumours with PD-L1 expression ≥50% vs <50% in non-squamous (nsq)-NSCLC treated with first-line tislelizumab (TIS) plus chemotherapy (CT) vs CT alone

作者：F. Cappuzzo, Shuaiji Lu, Yiyi Yu, Li Liang, K. Naicker, X. Lin, Xi Ma, Matthew T. Taylor, C.G.M. Ferreira, M. Reck · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.08.2499 · 研究领域：Cancer Immunotherapy and Biomarkers、Colorectal and Anal Carcinomas、PARP inhibition in cancer therapy

1875P RATIONALE-304: Baseline genetic alterations in tumours with PD-L1 expression ≥50% vs &lt;50% in non-squamous (nsq)-NSCLC treated with first-line tislelizumab (TIS) plus chemotherapy (CT) vs CT alone

1875P RATIONALE-304: Baseline genetic alterations in tumours with PD-L1 expression ≥50% vs <50% in non-squamous (nsq)-NSCLC treated with first-line tislelizumab (TIS) plus chemotherapy (CT) vs CT alone